Francesco Girelli
A5044774777- Rheumatoid Arthritis Research and Therapies
- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Lymphocytic Leukemia Research
- Autoimmune Bullous Skin Diseases
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
- Sarcoidosis and Beryllium Toxicity Research
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging and Pathology Studies
- Vasculitis and related conditions
- Inflammatory Myopathies and Dermatomyositis
- Eosinophilic Disorders and Syndromes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Otitis Media and Relapsing Polychondritis
- Platelet Disorders and Treatments
- Autoimmune and Inflammatory Disorders Research
- Urticaria and Related Conditions
- Pharmaceutical studies and practices
- Systemic Lupus Erythematosus Research
- Mast cells and histamine
- Dermatologic Treatments and Research
- Skin Diseases and Diabetes
- Dermatological and Skeletal Disorders
Ospedale G.B. Morgagni - L.Pierantoni
2011-2025
Azienda Unità Sanitaria Locale Della Romagna
2020
Presidio Ospedaliero
2017
Azienda USL di Bologna
2017
Center for Rheumatology
2013
Ospedale per gli Infermi
2004-2005
Recent evidence suggests that idiopathic nonspecific interstitial pneumonia (iNSIP) is a distinct clinical entity amongst other pneumonias, and some data seem to suggest possible pathogenetic role of autoimmunity. The aim the present study was assess if iNSIP might represent an early lung manifestation autoimmune disease. After initial review cases found in medical records database by searching for term "NSIP" (n = 63), 37 were identified, re-evaluated using dynamic integrated...
Objective To describe demographic, clinical and laboratory features of systemic sclerosis sine scleroderma (ssSSc) in a large multicentre (SSc) cohort. Methods Data involving 1808 SSc patients from Italian Systemic PRogression INvestiGation registry were collected. The ssSSc was defined by the absence any cutaneous and/or puffy fingers. Clinical serological compared with limited (lcSSc) diffuse (dcSSc) subsets. Results Among SSc, only 61 (3.4%) classified as having (F/M=19/1). Time Raynaud’s...
Background: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for treatment of rheumatoid arthritis (RA). However, data on retention rate TOFA therapy are still far from definitive. Objective: The goal this study is add new real-world in a cohort RA patients followed long period time. Methods: A multicenter retrospective subjects treated with as monotherapy or combination conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) conducted 23 Italian...
Objective Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed DU could reduce the incidence of PAH a large SSc cohort from SPRING registry. Methods Patients with registry, meeting ACR/EULAR 2013 classification criteria data on onset, status, exposure, at least one-year follow-up between 2015 2020, no known baseline were included. was diagnosed right...
Objective There is still a great deal to learn about the influence of sex in systemic sclerosis (SSc). In this respect, national registries provide large and homogeneous patient cohorts for analytical studies. We therefore investigated wide-ranging well-characterized SSc series with aim identifying differences disease expression, special focus on demographic, clinical, serological characteristics. Methods A multicenter cohort 2281 patients, including 247 men, was recruited Italian Systemic...
Drug Rash Eosinophilia Systemic Symptoms (DRESS) syndrome is a systemic hypersensitivity reaction characterized by exfoliative dermatitis and maculopapular rash, lymphadenopathy, fever, eosinophilia, leukocytosis, involvement of internal organs as liver, lung, heart, kidney; the disorder starts within 2-6 weeks after taking drug with an incidence that ranges from 1/1000 to 1/10000 exposures. Fatal cases are reported. The exact pathogenesis DRESS not completely understood, while it reported...
This multicentre study aimed to investigate the overall mortality of combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis (SSc) compare CPFE-SSc characteristics with those other SSc subtypes (with interstitial lung disease-ILD, or neither).Chest CTs, anamnestic data, immunological profile function tests patients were retrospectively collected. Each chest CT underwent a semiquantitative assessment blindly performed by three radiologists. Patients clustered four groups:...
Background/Objectives: The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, US Food Drug Administration (FDA) raised concerns about safety TOFA after its approval. This prompted European Medicines Agency (EMA) to issue two warnings limiting use, then extended a third warning all JAKi in patients at high risk developing serious adverse effects (SAE). These...
We evaluated the 3-year drug survival and efficacy of biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic (PsA) ankylosing spondylitis (AS) patients, previously treated with etanercept (ETA). Drug rate was calculated using Kaplan–Meier method Cox proportional hazard models were developed to examine predictors SB4 discontinuation. 236 patients (120 RA, 80 PsA 36 AS), aged 60.7 ± 13.8 years an ETA duration 4.1 3.4 included. The retention for 94.4%, 88% 86% AS, RA respectively, no...
Intravenous iloprost has been widely used for the treatment of systemic sclerosis peripheral vasculopathy. No agreement found on regimen and dosage intravenous in different scleroderma subset conditions. This study aimed to evaluate modalities administration within a large cohort patients from SPRING Registry identify any associated clinical-demographic, instrumental or therapeutic data.
The recent introduction of ABP 501, an adalimumab biosimilar, in the treatment rheumatic diseases was supported by a comprehensive comparability exercise with its originator. On other hand, observational studies comparing and 501 inflammatory arthritis are still lacking. main aim this study is to compare clinical outcomes adalimumab, both originator large cohort patients affected autoimmune real life setting. We retrospectively analysed baseline characteristics retention rate who received at...
To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response PsA patients and analyze the predictors clinical response.All consecutive treated with fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, disease activity at baseline, 6 months, 12 months...
Background A subgroup of IPF patients can meet IPAF criteria (features suggesting an underlying autoimmune process without fulfilling established for a CTD). This study was aimed to evaluate whether IPAF/IPF compared differ in clinical profile, prognosis and disease course. Methods is retrospective, single center, case–control study. We evaluated 360 consecutive (Forlì Hospital, between 1/1/2002 28/12/2016) characteristics outcome IPF. Results Twenty-two (6%) met criteria. were more...
<h3>Background:</h3> In the last years, there was a dramatic increase of advanced DMARDs for psoriatic arthritis (PsA). There are many b/tsDMARDs with different mechanisms action (MoA) to consider after failure first line therapy. As consequence, rheumatologists can implement cycling (same MoA) or swap strategy. <h3>Objectives:</h3> The aim this real world based study is investigate if, TNF inhibitor (TNFi), another TNFi an interleukin 17 (IL17i) most effective choice (from clinical practice...
<h3>Background:</h3> Since 2022 clinicians have been consistently aware by the European Medical Agency (EMA) of prescribing Jak-inhibitors (JAKi) after assessing a risk/benefit ratio, especially in patients with rheumatoid arthritis (RA)<sup>1</sup>. Nevertheless, during last years, uptake selective JAKis has increased, although limited data regarding differences between and unselective are available to date. <h3>Objectives:</h3> To assess JAKIs terms discontinuation's rate....
Background and Objectives: The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Safety concerns, particularly related cardiovascular cancer risks, prompted need additional investigation in real-world clinical settings. This...
Introduction: Upadacitinib (UPA) is an oral Janus kinase inhibitor (JAKi) recently approved for the treatment rheumatoid arthritis (RA) treatment. Although registrational studies have demonstrated efficacy of UPA in RA, data on long-term retention rate this drug are still lacking. Objective: The objective his study was to evaluate real-world patients with analyze possible reasons discontinuation, and attempt identify independent factors possibly associated persistence Methods: We conducted a...
Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important choose most effective treatment according patients' characteristics. Apremilast recommended in PsA with moderate activity. In clinical practice, suitable patients for apremilast are those affected by peripheral oligo-articular arthritis. However, not so straightforward definitely identify this phenotype. Musculoskeletal ultrasound (MUS) good tool detecting...